EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PD1CD28 chimeric molecule enhances EGFRvⅢ specific CAR-T cells in xenograft experiments in mouse models

Wanqiong Chen iD, Na Xian, Ningning Zhao, Qiong Zhang, Yunlu Xu

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0310430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Wanqiong Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Quanzhou Medical College, Quanzhou, Fujian, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, ErbB Receptors, Glioblastoma, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Quanzhou City Science and Technology Program, Natural Science Foundation of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the years, CAR-T cell therapy has achieved remarkable success in treating hematological malignancies. However, this efficacy has not been replicated in the context of glioblastoma (GBM). In this study, a PD1CD28 chimeric molecule was introduced into EGFRvⅢ-directed CAR-T cells, generating EGFRvⅢ-P2A-PD1CD28 CAR-T cells. Notably, this modification significantly increased IL-2 secretion and enhanced antigen-dependent activation of CAR-T cells, especially when programmed cell death ligand 1 (PD-L1) was present in vitro . In addition, the in vivo xenograft experiments revealed that the PD1CD28 chimeric molecule played a pivotal role in reducing recurrence rates, effectively controlling recurrent tumor volume, and ultimately prolonging the survival of mice. Collectively, these findings suggest that EGFRvⅢ-directed CAR-T cells co-expressing the PD1CD28 chimeric molecule have the potential to significantly enhance the treatment efficacy against GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenErbB ReceptorsGlioblastomaImmunotherapy, AdoptiveProgrammed Cell Death 1 ReceptorAnimalsHumansMiceCell Line, TumorInterleukin-2Receptors, Chimeric AntigenT-LymphocytesXenograft Model Antitumor Assays

Substanzen

B7-H1 AntigenCD274 protein, humanepidermal growth factor receptor VIIIErbB ReceptorsInterleukin-2Programmed Cell Death 1 ReceptorReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • School of Pharmacy, Quanzhou Medical College, Quanzhou, Fujian, China.
  • Institute of Immunotherapy, Fujian Medical University, Fuzhou, Fujian, China.
  • Tcelltech Biological Science and Technology Inc., Fuzhou, Fujian, China.
  • Laboratory Animal Center, Fujian Medical University, Fuzhou, Fujian, China.
  • School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China.
  • Laboratory of Snake Venom, The Center of Translational Hematology, Fujian Medical University, Fuzhou, Fujian, China.

ORCID-Profile: Wanqiong Chen

Förderung

  • Quanzhou City Science and Technology Program
  • Natural Science Foundation of Fujian Province

Zitieren

APA

Chen, W., Xian, N., Zhao, N., Zhang, Q., & Xu, Y. (2024). PD1CD28 chimeric molecule enhances EGFRvⅢ specific CAR-T cells in xenograft experiments in mouse models. PLOS ONE. https://doi.org/10.1371/journal.pone.0310430

Vancouver

Chen W, Xian N, Zhao N, Zhang Q, Xu Y. PD1CD28 chimeric molecule enhances EGFRvⅢ specific CAR-T cells in xenograft experiments in mouse models. PLOS ONE. 2024. doi:10.1371/journal.pone.0310430

BibTeX
@article{Chen2024,
  author = {Chen, Wanqiong and Xian, Na and Zhao, Ningning and Zhang, Qiong and Xu, Yunlu},
  title = {PD1CD28 chimeric molecule enhances EGFRvⅢ specific CAR-T cells in xenograft experiments in mouse models},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0310430}
}
Kostenlos starten →